Claire Arnold

Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML

Jad Othman, Nicola Potter, Adam Ivey et al. · Blood · 2024 · 63 citations · Full text

Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission

Jad Othman, Nicola Potter, Adam Ivey et al. · Blood · 2024 · 62 citations · Full text

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon et al. · Blood Advances · 2023 · 50 citations · Full text

Secondary Aml, Mixed-phenotype Acute Leukemia, Genetic Epidemiology +16

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 31 citations · Full text

Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort

Olga Michail, Patrick McCallion, Julie McGimpsey et al. · Journal of Clinical Pathology · 2020 · 17 citations